AstraZeneca: promising results for Airsupra in asthma

(CercleFinance.com) - AstraZeneca announces that the Independent Data Monitoring Committee has recommended the early termination of the BATURA Phase IIIb trial due to the clear efficacy of Airsupra.


This inhaled medication, combining albuterol and budesonide, showed a significant reduction in the risk of severe exacerbation in mild or intermittent asthmatic patients compared with albuterol alone.

No new safety issues were identified.

Results will be presented at the ACAAI annual meeting in October 2024.

Airsupra is already approved in the US to reduce the risk of exacerbations in adults with asthma.


Copyright (c) 2024 CercleFinance.com. All rights reserved.